Chemotherapy-Induced Tumour Lysis Syndrome in Gastric Adenocarcinoma with Diffuse Liver Metastases: A Case Report

BACKGROUND Rasburicase (recombinant urate oxidase) has been proven to be an effective therapy for prevention of tumour lysis syndrome (TLS). The recommended daily dosing regimen of rasburicase is 0.2 mg/kg/day for 5 days which is expensive and unaffordable to many patients in the developing countries. The purpose of the present study was to evaluate the effect of single 1.5 mg dose rasburicase in the management of tumour lysis syndrome. METHODS This is a follow-up study done at our institute. Fifty (50) patients with tumour lysis syndrome who received rasburicase from August 2015 to January 2020 were enrolled in this study RESULTS Single dose of rasburicase is effective in decreasing serum uric acid level in significant number (N = 41) of patients. Percentage of patients having uric acid less than 7 mg after single dose of rasburicase in 48 hours - 82.9 % (N = 34) while 17 % (N = 7) were found to have uric acid levels of more than 7 mg/dl. The percentage of patients with uric acid levels more than 7 mg/dl reduced from 36.5 % after 24 hours to 17 % after 48 hours. This indicates that the uric acid levels show a declining trend even after 24 hours without giving an additional dose of rasburicase. There was no relationship between uric acid levels at 24 hours and percentage change in creatinine level from baseline to 24 hours (correlation coefficient (r) = -0.047, P = 0.770. Patients who required additional dose (N = 9) had high base line value of uric acid and their high value was maintained over the follow up period of three days. Patients with pre exiting kidney disease and high level of baseline uric acid also needed dialysis (N = 3). CONCLUSIONS In majority of patients, a single 1.5 mg dose of rasburicase is an effective way to reduce raised uric acid in appropriate circumstances. KEYWORDS Single Dose, Recombinant Urate Oxidase, Uric Acid, Leukemia, Tumour Lysis Syndrome, Rasburicase

Download Full-text

Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer

BMJ Case Reports ◽

10.1136/bcr-2013-009532 ◽

2013 ◽

Vol 2013 (apr23 1) ◽

pp. bcr2013009532-bcr2013009532 ◽

Cited By ~ 5

Author(s):

M. Camarata ◽

R. Davies ◽

S. Copley ◽

S. Blagden

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Tumour Lysis Syndrome ◽

Tumour Lysis

Download Full-text

Alopecia Neoplastica due to Gastric Adenocarcinoma Metastasis to the Scalp, Presenting as Alopecia: A Case Report and Literature Review

Annals of Dermatology ◽

10.5021/ad.2014.26.5.624 ◽

2014 ◽

Vol 26 (5) ◽

pp. 624 ◽

Cited By ~ 10

Author(s):

Jung-Hee Kim ◽

Min-Joong Kim ◽

Woo-Young Sim ◽

Bark-Lynn Lew

Keyword(s):

Case Report ◽

Literature Review ◽

Gastric Adenocarcinoma

Download Full-text

Intracholecystic papillary-tubular neoplasm in a patient with choledochal cyst and anomalous pancreaticobiliary junction: case report

BJR|case reports ◽

10.1259/bjrcr.20180079 ◽

2019 ◽

Vol 5 (2) ◽

pp. 20180079

Author(s):

Marta Reis de Sousa ◽

Inês Santiago ◽

Maria J Barata ◽

Mireia Castillo ◽

Celso Matos

Keyword(s):

Case Report ◽

Bile Duct ◽

Gastric Adenocarcinoma ◽

Choledochal Cyst ◽

Histopathological Analysis ◽

Gallbladder Neoplasms ◽

Choledochal Cysts ◽

Bile Duct Dilatation ◽

Duct Dilatation ◽

Anomalous Pancreaticobiliary Junction

A 75-year-old female incidentally presented with an enhancing intraluminal gallbladder mass, main bile duct dilatation and anomalous pancreaticobiliary junction (APBJ) during the staging of gastric adenocarcinoma. Histopathological analysis confirmed the diagnosis of intracholecystic papillary-tubular neoplasm. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder are rare gallbladder neoplasms, defined as intramucosal, preinvasive, exophytic, mass forming lesions. An association between choledochal cysts and anomalous pancreaticobiliary junction with gallbladder neoplasms is well known, and this case potentially illustrates gallbladder carcinogenesis related to these biliary anomalies.

Download Full-text